A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups

Tuberculosis

Volumn 99, Issue , 2016, Pages 81-91

  Auguste, Peter ^a   Tsertsvadze, Alexander ^a   Court, Rachel ^a   Pink, Joshua ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cost effectiveness; Decision analytical modelling; Latent tuberculosis; Systematic review

Indexed keywords

COST EFFECTIVENESS ANALYSIS; EMBASE; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LATENT TUBERCULOSIS INFECTION; MEDLINE; PRIORITY JOURNAL; REVIEW; TUBERCULIN TEST; ADOLESCENT; ADULT; AGE; AGED; CHILD; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DECISION TREE; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; IMMUNOLOGY; INFANT; MARKOV CHAIN; MASS SCREENING; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MIGRANT; PREDICTIVE VALUE; PRESCHOOL CHILD; PREVALENCE; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BACTERIOLOGICAL TECHNIQUES; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; EMIGRANTS AND IMMIGRANTS; HEALTH CARE COSTS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; LATENT TUBERCULOSIS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; YOUNG ADULT;

EID: 84969528841     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2016.04.007     Document Type: Review

References (19)

1. S.H. Kim, S.O. Lee, J.B. Park, I.A. Park, S.J. Park, S.C. Yun, J.H. Jung, Y.H. Kim, S.C. Kim, S.H. Choi, J.Y. Jeong, Y.S. Kim, J.H. Woo, S.K. Park, J.S. Park, and D.J. Han A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients [Erratum appears in Am J Transplant. 2011 Nov;11(11):2541] Am J Transpl 11 9 2011 1927 1935
2. H. Mahomed, T. Hawkridge, S. Verver, D. Abrahams, L. Geiter, M. Hatherill, R. Ehrlich, W.A. Hanekom, and G.D. Hussey The tuberculin skin test versus QuantiFERON TB Gold in predicting tuberculosis disease in an adolescent cohort study in South Africa [Erratum appears in PLoS One. 2011;6(6). doi:10.1371/annotation/b371be66-de38-4ed6-b440-d27c9d7e552c] PLoS One 6 3 2011 e17984
3. National Collaborating Centre for Chronic Conditions, Centre for Clinical Practice at NICE Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. CG117 2011 cited; Available from: http://www.ncbi.nlm.nih.gov/books/NBK97852/
4. M. Pareek, M. Bond, J. Shorey, S. Seneviratne, M. Guy, P. White, A. Lalvani, and O.M. Kon Community-based evaluation of immigrant tuberculosis screening using interferon gamma release assays and tuberculin skin testing: observational study and economic analysis Thorax 68 3 2013 230 239
5. M.C. Weinstein, B. O'Brien, J. Hornberger, J. Jackson, M. Johannesson, C. McCabe, and B.R. Luce Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies Value Health 6 1 2003 9 17
6. HTA 13/178/01: Accurate diagnosis of latent tuberculosis in children, in people who are immunocompromised or at risk from immunosuppression, and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation 2014 cited; Available from: http://www.nets.nihr.ac.uk/projects/hta/1317801
7. D. Husereau, M. Drummond, S. Petrou, C. Carswell, D. Moher, D. Greenberg, F. Augustovski, A.H. Briggs, J. Mauskopf, and E. Loder Consolidated health economic evaluation reporting standards (CHEERS) statement Eur J Health Econ 14 3 2013 367 372
8. Z. Philips, L. Ginnelly, M. Sculpher, K. Claxton, S. Golder, R. Riemsma, N. Woolacoot, and J. Glanville Review of guidelines for good practice in decision-analytic modelling in health technology assessment Health Technol Assess 8 36 2004 1 158 iii-iv, ix-xi
9. A. Kowada Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy Mol Diagn Ther 14 6 2010 367 373
10. A. Kowada Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening Mol Diagn Ther 16 3 2012 181 190
11. A. Kowada Cost effectiveness of the interferon- release assay for tuberculosis screening of hemodialysis patients Nephrol Dial Transpl 28 3 2013 682 688
12. A. Kowada Cost effectiveness of interferon- release assay for TB screening of HIV positive pregnant women in low TB incidence countries J Infect 68 1 2014 32 42
13. B.L. Laskin, J. Goebel, J.R. Starke, D.P. Schauer, and M.H. Eckman Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children Am J Kidney Dis 61 1 2013 22 32
14. B.P. Linas, A.Y. Wong, K.A. Freedberg, and C.R. Horsburgh Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States Am J Respir Crit Care Med 184 5 2011 590 601
15. A. Swaminath, N. Bhadelia, and Y.C. Wang Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease Inflamm Bowel Dis 19 11 2013 2444 2449
16. A.M. Mandalakas, A.C. Hesseling, R.P. Gie, H.S. Schaaf, B.J. Marais, and E. Sinanovic Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting Thorax 68 3 2013 247 255
17. A.H. Briggs, and A.M. Gray Handling uncertainty when performing economic evaluation of healthcare interventions Health Technol Assess 3 2 1999 1 134
18. J.R. Campbell, T. Sasitharan, and F. Marra A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection Appl Health Econ Health Policy 13 4 2015 325 340
19. R. Diel, N. Lampenius, and A. Nienhaus Cost effectiveness of preventive treatment for tuberculosis in special high-risk populations Pharmacoeconomics 33 8 2015 783 809